Consistent with these findings, depleting cyclin A2 sensitized MCF-7 and MDA-MB-231 cells to DNA damaging agent and PARP inhibitors (Figure 6), a drug class that has shown success against breast cancer. Here, CCNA2 is linked to breast cancer.